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ABSTRACT _
In the field of outcomes research, modeling is increas-
ingly being used to assess costs and outcomes associ-
ated with healthcare interventions. However, there is
little standardization with regard to modeling practices,
and the quality and usefulness of economic and health
outcomes models may vary. \X7e propose the following
set of recommendations for good modeling practices to
be used in both the development and review of models.
These recommendations are divided into three sections:
criteria to be addressed before model development or
I n the current environment of medical cost con-tainment, it is no longer sufficient to demonstrate
the clinical efficacy of new medical technologies.
Insurers, third-party payers, and government agen-
cies are increasingly demanding information re-
garding the effectiveness and cost-effectiveness of
new medical technologies relative to their benefits.
To obtain this information in a timely manner,
models are being used to explore the factors influ-
encing outcomes and costs associated with new
medical therapies. In the context of outcomes re-
search, a model is a structured representation of
real world healthcare activities, incorporating event
probabilities, resource utilization, costs, and pa-
tient outcomes. These models are used to evaluate
the impact of medical interventions on costs and
other outcomes under conditions of uncertainty.
The primary goal of such models is to provide
additional information for decision makers, who
may include government officials, health system
managers, healrhcare providers, or patients. Mod-
els can also force decision makers to define the
treatment options and likely outcomes associated
with any healthcare decision. The quantification
of healthcare decisions can facilitate communica-
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initial review; criteria used during model development
or evaluation; and criteria used following model devel-
opment. These recommendations also include examples
regarding different modeling techniques and practices
as well as a checklist (see appendix) to assess model
correspondence with the recommendations. We hope
that the use of good practice recommendations for
modeling will not only improve the development and
review of models but also lead to greater acceptance of
this methodology.
tion between patients and healrhcare providers,
improving the quality of care [11.
Recently, guidelines for the performance of phar-
macoeconomic analyses have been published in
the United States [2]. A number of authors have
called for the development of guidelines for the
design and/or evaluation of economic models (3).
As discussed by Sheldon [3], "We have not yet de-
veloped check lists to be able to critically appraise
decision analytic models." Recent reports have ex-
plored a number of related issues, including uses,
problems, and importance of modeling. However,
only one recent publication has begun to suggest
appropriate model guidelines [41. In this paper, we
propose recommendations for "good practices"
for healthcare model development and evaluation.
While many of these recommendations pertain to
modeling in general, the paper focuses only on
those models developed to assess or compare the
impacts (clinical, economic, and quality of life) of
medical technologies.
The recommendations have been separated into
three categories based on the time frame for their
appropriate use: 1) before model development; 2)
during model development; and 3) after model de-
velopment. Clearly, all aspects of model design and
evaluation cannot be separated into single and ex-
clusive time periods. However, this framework is
intended to help model designers and reviewers fo-
cus on the key criteria during three natural phases
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of the development/evaluation process. A checklist
is included at the end of the paper to help model de-
velopers and evaluators focus on key components
of models.
Criteria Used before Model Development
These recommendations refer to criteria that should
be addressed before model construction (or review)
begins. Good practice requires that the decisions
made in the planning and initial development of a
model be appropriate; if these decisions are flawed,
the value of the model will be greatly limited regard-
less of subsequent development efforts.
Study Question
When beginning to design or evaluate a model, the
question that the model is to answer must be ex-
plicitly stated to insure that the reason for devel-
oping the model is made clear. The disease(s) or
condition(s} being modeled, interventions in ques-
tion, specific study populations, and study per-
spective need to be stated. Good practices cannot
result unless there is a clear starting basis.
Clinical Relevance
Once the study question is presented, it must be ex-
amined for reasonableness. The issue addressed by
the model must have clinical face validity; that is,
the scenario or strategy to be modeled should not
be irrelevant or even harmful from a clinical per-
spective (e.g., the routine use of antibiotics to treat
viral infections). In addition, the selected popula-
tion must be relevant for the specified clinical
condition. Assessment of clinical relevance will gen-
erally require involvement of clinicians, often spe-
cialists, to confirm that the study question is rea-
sonable and appropriate. However, policy makers
may also provide important contributions in assess-
ing the relevance of a study question within social,
political, and budgetary constraints. For example,
while childhood immunization for common infec-
tious diseases (such as measles) is clinically reason-
able, it is not relevant to evaluate the costs and out-
comes of childhood immunization in a population
that will not accept immunization (e.g., certain reli-
gious groups). Clinical relevance is a question for
all types of socioeconomic studies but is of particu-
lar importance in modeling, as exploration of irrel-
evant or nonsensical treatment options has more




A fundamental question in designing or evaluating
a model is whether modeling is the best approach.
Given the question to be answered (from Study
Question), it must be determined whether model-
ing is the most (or only) practical approach. Can
the healthcare question be answered by a model?
While many healrhcare problems can be general-
ized to a series of simplified, defined steps, much
of medicine involves intuition. Models can be de-
veloped only when the alternative interventions,
outcomes, and probabilities can be specified or at
least estimated. When the basis of healthcare deci-
sions involves intuition or other undefinable fac-
tors, models are less successful [5}.
Furthermore, could the question be answered
by using available retrospective data? Is it feasible
and realistic to explore the issue in a prospective
study, either in the context of a clinical trial or a
naturalistic study? As a corollary, it should he
noted that it is usually not possible to collect all
relevant outcomes data only from well-controlled
clinical trials.
As discussed in a number of reports [6-8],
modeling is most appropriate for certain specified,
select purposes. Purposes for modeling discussed
by Buxton et al. [61 are:
• Extrapolating either beyond the time period for
which data are available or from intermediate
clinical endpoints to final outcomes;
• Generalizing results to other settings;
• Performing analysis when other data (such as
direct comparisons) are not available.
Another important reason for modeling is to
extrapolate trial data to more real-world settings
and to update study findings as subsequent data
become available. Unlike retrospective or prospec-
tive studies, models can be changed to incorporate
new information and produce revised projections.
In addition, models can be used to evaluate the im-
pacts of events that may not be observed in short-
term prospective studies, such as unusual side ef-
fects or longer term compliance with treatment
regimens. Finally, the question of time and ex-
pense of performing the study using an alternative
methodology should be considered. While a natu-
ralistic prospective study may be a feasible, realis-
tic, even ideal methodology to evaluate a given
healthcare intervention, the cost and time needed
to perform such a study may be prohibitive. Deci-
sion makers cannot wait to obtain these long-term
results; by the time prospective studies are com-
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pleted, their results may no longer be useful. For
example, Hillner et al. [9] modeled the outcomes
of autologous bone marrow transplant for ad-
vanced breast cancer patients. These model results
were obtained years before the prospective study
findings. Similarly, Djulbegovic et al. PO] per-
formed a decision analysis model to evaluate opti-
mal therapy for large-cell lymphoma 7 years before
the conclusion of the related clinical trial. Kupper-
man et al. [111 developed a model estimating the
conditions under which second generation implant-
able defibrillators would be cost-effective. Thus, the
optimal results obtained from modeling may be
more useful than ideal results obtained years later
from another study methodology.
Available Information
In approaching the development of a model, the
breadth and sources of information pertaining to
the condition and/or intervention under study must
be assessed. These include the epidemiology of the
disease, risk factors, short-term effects, and re-
lated long-term outcomes. The sources of informa-
tion regarding the condition and intervention must
also be considered. Limited availability of infor-
mation should not be considered an insurmountable
barrier to model development; models are most
needed when little information is available from
other sources. However, as the specifics of model
development will be influenced by available infor-
mation, this must be explored early in the model-
ing process.
Model Scope
Model scope refers to the limits or boundaries of a
model: the time frame, population/subpopulations,
perspective, comparators, setting, country or re-
gion, payment system, index patients or disease
characteristics (e.g., asymptomatic vs symptomatic
individuals), and other factors that will determine
the type and extent of costs and events to include in
the model. The scope of the model needs to be de-
termined at the onset of the study. Scope will de-
pend on the disease/condition and intervention un-
der study [4]. Model time frames can involve brief
periods (e.g., a 7-day course of antibiotic therapy)
or a much longer period (from diagnosis until death
years or decades later for a chronic condition). Use
of longer time periods requires discounting of costs
and outcomes; discount rates mnst be specified as
part of the model scope. Interventions can be exam-
ined over an entire population or only for a high-
risk subpopulation. All potential comparators can
be included (e.g., any parenteral antibiotic used to
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treat gram-negative pneumonia) versus only com-
parators within a specified class or group (e.g., only
parenteral cephalosporins). In some cases, a model
will be developed to evaluate differences in scope,
for example, the impact of evaluating different ages
to start a screening program or different time peri-
ods for treatment follow-up [121. Model perspec-
tive also needs to be determined and clearly stated.
Many believe that a societal perspective [21 should
be used; however, the perspective should agree with
the purpose of the model. A model to aid internal
decision making may be less helpful if broad alloca-
tion of health resources is considered.
Much of the model scope may be determined
by the available data; alternatively, models may be
developed to generate estimates of outcomes or
other parameters (such as event probabilities)
where none exist. Other aspects of model scope are
at the discretion of the modeler, but reasons for
each choice must be made clear.
Model Type
Appropriate model development and evaluation
will be highly influenced by the selection of the
type of model. Each type of model has optimal
uses based on specific advantages and disadvan-
tages. A number of model taxonomies or classifi-
cation systems have been suggested (see, for exam-
ple, [12]). The classification presented here focuses
on differentiating characteristics that are relevant
to the practical aspects of model development and
review. These classifications are not mutually ex-
clusive; for example, prescriptive models can be
epidemiologic or decision analysis models, deter-
ministic or stochastic models. Models can thus be
classified simultaneously using multiple criteria.
Intended Use of Model. Descriptive models are
designed to predict or illustrate the results of a clini-
cal process, in contrast to prescriptive models, which
are used to compare two or more interventions to es-
timate the optimal treatment course [71. For exam-
ple, a descriptive model may be developed to assess
the average resources used (and associated costs) for
treating a specific condition or performing a particu-
lar procedure, such as coronary artery bypass graft
(CABG) surgery, in order to plan for future alloca-
tion of resources. Conversely, a prescriptive model
can compare the potential costs and outcomes for
multiple treatment alternatives, such as assessing the
differential impacts of antiplatelet therapy, percuta-
neous transluminal coronary angioplasty (PTCA), or
CABG for coronary artery occlusion, and can rec-
ommend the optimal treatment path. A descriptive
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model is often simpler and involves less uncertainty
than a prescriptive model; however, its use is limited
to examining current treatment practices. Prescrip-
tive models are generally more flexible and allow ex-
ploration of areas of uncertainty (e.g., changing key
probabilities) in order to determine optimal treat-
ment pathways. Prescriptive models often contain a
number of descriptive models, each comparing an al-
ternative strategy. Sharples et al, [13] combined four
descriptive models for treatment following cardiac
transplantation into a prescriptive model comparing
alternative therapies for maintenance and antirejec-
tion treatment.
With respect to intended use, Weinstein [141
also distinguishes between clinical decision models,
designed to guide clinicians or patients, and policy
models, which will assist persons and organiza-
tions (such as government agencies) with allocating
healrhcare resources. Simpson [15] similarly differ-
entiates three types of model use: to evaluate treat-
ment alternatives; to develop clinical guidelines;
and to assess population costs for policy purposes.
The structure of clinical and policy models may be
identical; however, the perspective of the model,
and thus the costs included, often differ. A clinical
decision model may include only direct costs expe-
rienced by the patient or medical care system,
while a policy model may employ a societal per-
spective and can include broader costs such as loss
of income or care giver burden.
Disease Progression uersus Treatment Compari-
sons. A broad distinction can be made between ep-
idemiologic models and decision analysis models.
Epidemiologic models represent the progression of
a disease or condition over time within a specified
population. These models project the future out-
comes for a given individual, based on his or her
sociodemographic, behavior, and clinical character-
istics (i.e., risk factors). Data from long-term obser-
vational studies (e.g., the Framingham study) for
cases, deaths, and other naturalistic events are used;
clinical decisions are generally not explicitly included
[2]. By contrast, decision analysis models evaluate
the costs and health outcomes associated with
healthcare intervention strategies or treatment pat-
terns for either an individual or a population cohort.
Outcomes from decision analysis models commonly
include costs, life years, quality-adjusted life years
(QALYs), and other measures associated with
healthcare interventions. The majority of work in
health outcomes modeling has involved decision
analysis models. For health outcomes analyses in-
volving extrapolation of short-term findings to long-
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term clinical conditions, however, it is often neces-
sary to combine epidemiologic and decision analysis
modeling. For example, in treating hypertension, a
decision analysis model may be used to evaluate
short-term costs and outcomes (normalization of
blood pressure). Based on the resultant blood
pressure, the probability of long-term adverse out-
comes, such as development of renal failure, will
be predicted using an epidemiologic modeL A deci-
sion analysis model would then be used again to
determine the costs and outcomes of treatment al-
ternatives for development of renal failure and
other outcomes following therapy for hypertension.
Both decision analysis and epidemiologic models
are generally based on population-level data; apply-
ing population data to individual patients is a limi-
tation that modeling shares with many other scien-
tific techniques.
Use of Probabilities. Models can be classified into
two broad groups based on use of probability. De-
terministic models use probabilities based on fixed
values (point estimates). That is, the probability of
experiencing any branch at any node in a model
is a single, fixed value. Therefore, every time the
model is run, the results are identical, except, of
course, when sensitivity analyses are conducted to
vary the probabilities in order to explore the im-
pact of parameter uncertainty. Incontrast, stochas-
tic models include node probabilities based on nu-
merical distributions [71. At some or all nodes in a
stochastic model, the probability of experiencing a
branch is not a single fixed value but a range of
values from a defined distribution. This means that,
each time the model is run, different values may
be produced at each stochastic node, resulting in
different proportions of patients experiencing the
model branches and subsequently incurring differ-
ent costs and outcomes. If the mean values of the
distributions in a stochastic model are identical to
the fixed probabilities in a deterministic model,
both models will produce the same mean results
when the stochastic model is run multiple times.
However, the stochastic model will also produce a
variance around the mean value from which a confi-
dence interval may be determined. Since a determin-
istic model produces the same results each time it is
run, no variance will be determined. Models can in-
clude both deterministic and stochastic probabilities.
In many cases, it is reasonable to use only a point
estimate or a range of values for the likelihood of a
given modeled event. Conversely, it may be difficult
to determine the distribution of an event's likeli-
hood. In such cases, a deterministic approach is ap-
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propriate. Deterministic models are simpler than
stochastic ones, require less expertise to develop,
and can be analyzed using less complex computer
software. The main advantage of stochastic models
is that, as discussed above, repeated sampling from
the probability distributions in such models (e.g.,
using Monte Carlo simulation) can be used to evalu-
ate the uncertainty around the modeled outcomes.
The majority of models used to evaluate health-
care costs and outcomes are deterministic. In real-
ity, most probabilities and other variables used in
models are not single data points but represent val-
ues from numerical distributions; if data on these
distributions were available, more models would
use a stochastic approach. Unfortunately, the dis-
tribution of these variables is seldom known. Dou-
bilet et al. [161 described a methodology for con-
verting probability point estimates and a single
bound (e.g., the upper 95% confidence interval on
the point estimate) to a probability distribution
that can be used for stochastic analysis. However,
determination of the bound may be based on sub-
jective judgment and thus may produce a biased
probability distribution. Furthermore, probability
distributions for variables within a model may be
linked or correlated. In these cases, replacing point
estimates with independent probability distribu-
tions would be inappropriate. Attempts to increase
model sophistication by using speculative proba-
bility distributions are likely to increase model un-
certainty. Some authors have argued that stochas-
tic approaches lead to more robust models and are
most appropriate. However, our view is that un-
less good data are readily available on distribu-
tion functions of model variables, the additional
time, expense, and complexity involved in stochas-
tic modeling are not worth the gain in precision.
Thus we recommend use of deterministic models
in most circumstances.
Use of Time. Others, such as Sonnenberg et al.
[4], have classified models by their design and use
of time as a model function. These include simple
trees, recursive trees, and Markov models. Simple
trees are most useful for modeling scenarios where
events or health states do not occur repeatedly and
the likelihood of events occurring in the model does
not change over time, such as most acute condi-
tions. For example, in a recently published model
evaluating antibiotic therapy for hospitalized pa-
tients 1171, each decision point is experienced only
once: resistant/sensitive bacterial infection, suffi-
cient/insufficient clinical improvement, and adverse
events/no adverse events. The probability of these
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events is fixed at the start of the model and does
not change over the course of antibiotic therapy.
Thus, a simple tree was the most appropriate model
type for this study.
Recursive trees involve treatment patterns or
health states that can repeat over time. A Centers for
Disease Control and Prevention (CDC)-sponsored
model of childhood vaccination is based on a re-
cursive tree. The model starts with the cohort of all
children born in the United States in a given year
and follows this cohort through age 18. Each year,
members of the cohort have a probability of devel-
oping the disease under study (e.g., rubella). The
probability of developing this disease changes each
year, but the events following developing the dis-
ease are identical. Each year individually is a sim-
ple tree; these single trees are repeated annually by
the model cohort with different probabilities of
disease development.
Markov modeling (or other types of state-transi-
tion modeling) is an extension of recursive trees for
more complex events occurring over time or for a
greater number of event repetitions. When models
involve multiple repeated events (e.g., the probabil-
ity of developing disease complications or experi-
encing alternative treatments each week for a year),
decision trees (graphic representations of models
showing each decision point and resultant treat-
ment pathways) become very complex and difficult
to draw or follow. Markov models can condense
the repeated branches into a more compact nota-
tion. For example, a model evaluating prostate can-
cer treatment may involve seven age groups, four to
five clinical and four to five pathological stage
groups, three clinical score groups, three to four ini-
tial treatments, two second-line treatments, and
three treatments for metastases. If such a model
were developed using a decision tree design, it
would require over 12,600 branches [151. In addi-
tion, Markov models permit more complex changes
in model probabilities, rates of resource utilization,
exposures to risk factors, and costs over time than
are feasible to include in recursive trees. Time in
Markov models is parsed into cycles, which are de-
fined uniform periods of time over which the model
is run. Markov models are often used to assess the
impact of new therapies on chronic conditions,
where patients may experience remissions, exacer-
bations, or disease progression over time. For exam-
ple, a Markov model was used to assess the impact
of taxotere chemotherapy for advanced breast can-
cer [18]. In this model, patients may respond to che-
motherapy, have stable disease, or have progressive
disease despite chemotherapy. For patients who re-
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spond to chemotherapy or have stable disease, the
disease may progress at some point in the future; the
likelihood of disease progression increases with time
in the responsive/stable health state. Markov model-
ing can be used to change the probability of disease
progression or remission over time.
One limitation of true Markov models is that
there is no "memory"; that is, the likelihood of a
given event at a specified time is not influenced by
the chain of preceding events. However, this con-
dition of no memory does not correspond to prob-
abilities observed in many treatment pathways.
For example, the likelihood of a patient with ma-
jor depression experiencing an acute depressive epi-
sode may depend on the number and timing of
previously experienced depressive episodes. Sharp-
Ies et aJ. f131 discuss a similar limitation to their
Markov model of treatment following cardiac trans-
plantation: While patients experiencing multiple
acute events following transplantation may be at
increased risk of developing chronic events, the
lack of memory in the Markov structure does not
permit the frequency of earlier acute events to influ-
ence the probability of later chronic consequences.
Decision analysis models involving time-depen-
dent events will often use "pseudo-Markov pro-
cesses," where the impact of prior events (memory)
is brought forward to affect subsequent events.
For example, patients with asthma may experi-
ence exacerbations (acute worsening of asthma
symptoms) over time. The likelihood of a patient
experiencing an exacerbation may depend, in part,
on the number of previous exacerbations. Thus, in
a pseudo-Markov asthma model, the probability
of patients in a stable health state experiencing ex-
acerbations will be influenced by the previous
number of exacerbations. This information will be
retained in the stable health state as the model
progresses to allow memory for the probability of
experiencing an exacerbation.
In general, models should involve the simplest
time structure feasible for appropriately assess-
ing the modeled condition(s) and intervention(s).
Recursive trees and Markov models are more
complex than simple trees, requiring more time
for development and greater modeling expertise.
However, these time-dependent models, once de-
veloped, can assess costs and outcomes of repeti-
tive treatment patterns more efficiently than a cor-
responding group of simple trees. Similarly, if
models require repetition of events or changes in
probabilities over time, Markov models are more
appropriate (and easier for evaluators to review)
than combinations of multiple simple trees. In ad-
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dition, a single model can involve multiple tech-
niques; for example, a model may begin as a sim-
ple tree with results then feeding in to a Markov
process.
Control of Variability. The amount of variability
that can be included or monitored within a model
varies by type of model. Simpler models (often de-
veloped using spreadsheets) generally involve one
or a small number of uniform cohorts passing
through a series of events; variability among mem-
bers of each cohort is not assessed. More complex
models (generally developed by using decision
analysis programs) often involve greater levels of
variability, both in model parameters and modeled
patients. In simulation models and linear program-
ming models (generally developed in specialized
programming languages, such as GPSS) each per-
son or object being modeled is followed separately.
Consequently, simulations allow users to include,
control, and monitor variability in patients and
model pathways. Simulations are often very com-
plex. These types of models are most applicable and
valuable when the response to a specified therapy is
likely to differ significantly between individuals with
similar characteristics. For example, individuals
with epilepsy may have similar demographic and
clinical characteristics, yet respond very differently
clinically or with respect to quality of life to the
same antiepilepric drug regimen. However, the
ability to include substantial variation in models is
often limited by the availability of data on such
variation. Subsequently, both simulation models
and linear programming have not been used exten-
sively in health outcomes, and therefore, we have
limited our discussion. As with use of time, we rec-
ommend that models use the simplest format (in-
volve the least amount of variability) needed to as-
sess the specified condition(s) and intervention(s).
We hope that in the future, simulations and other
related modeling techniques are used more fre-
quently in outcomes research.
Beyond the categories mentioned above, it may
be relevant to classify models based on the sources
of data, types of outcome, time frame, and other
factors related to model design and purpose. As
models are generally not classified using these di-
mensions, they are discussed above under Model
Scope.
Multiple types of models may often be appro-
priate to address a particular study question. Fur-
ther, the appropriate type or types may change
over time as available information increases and
model objectives change. For example, as addi-
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tional information on the temporal course of a
disease or healthcare intervention are elucidated,
it may be useful to expand a simple or recursive
tree model into a Markov model.
Previously Developed Models
It is not always necessary to develop new models;
it may be possible to use, modify, or integrate pre-
viously developed models [19J. This can poten-
tially decrease time and costs required for model
development as well as model errors (assuming
that the previously developed model is error-free,
which is not always a warranted assumption). In
addition, use of previously developed models may
be useful for validation (see Validation under head-
ing: Criteria Used after Model Development). Un-
fortunately, previously developed models are often
proprietary and are not available for general use.
Use of previously developed models in the devel-
opment of new models or model validation is real-
istic only when researchers are willing to share
earlier work or at least provide substantial infor-
mation on an earlier model's structure and param-
eters (see Transparency under heading: Criteria
Used while Developing Models).
Criteria Used while Developing Models or
Evaluating Model Design
Transparency
Information used in a model must be well docu-
mented and available for a review process. This
information should be presented in a clear and
easy-to-understand fashion, avoiding jargon for
reviewers not familiar with modeling terminology.
However, while many models are described in
published journals, model manuscripts are almost
always limited in length by the journals. Thus,
while a manuscript can present a limited overview,
nonproprietary details of the model need to be
available for reviewers and interested readers in a
technical appendix (which ideally would be avail-
able on the Internet). Information in a technical
appendix should include data sources, assump-
tions, event probabilities, healthcare resource utili-
zation, utilities, and costs and perspective.
Data Sources. Data used to develop models often
come from a variety of sources. To evaluate the
appropriateness of model parameters, the sources
of these parameters should be listed. As dis-
cussed in the following section, different sources
are associated with differing levels of credibility or
uncertainty.
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Assumptions. The validity of models often de-
pends on the reasonableness of their assumptions
[2], and the discrepancy observed between models
often is due to differences in assumptions. As such,
model assumptions require a high degree of trans-
parency. Assumptions having even minor impacts
on model parameters may have substantial effects
on projected outcomes [3]. At the completion of a
model, identifying all its assumptions may be diffi-
cult. Therefore, it is important to keep a log of as-
sumptions made during model development [19]
and to state them clearly.
Event Probabilities. The likelihood of any clini-
cal event in the model (e.g., success vs failure of a
therapy) must be present with its source(s).
Healthcare Resource Utilization. The rates and
types of healthcare resources used or incurred in
each disease state or condition included in the
model must be documented. It is important to
clearly separate resource utilization associated with
different health states or treatment pathways.
Utilities. If health utilities (preference weights)
are included in the model, the methodology used
to collect these utilities and the value for each
health state must be specified. Further specifica-
tions for collection of utilities are discussed below
under Data Quality.
Costs and Perspective. The sources for and per-
spective of all model costs, both direct and indirect
(e.g., total cost vs cost paid by an insurer vs cost re-
imbursed by the government), should be presented.
Unit costs for each medical resource as well as sum-
mary medical costs should be provided.
The full extent of model transparency would be
to provide electronic copies of the model for re-
view. While this would allow complete evaluation
of the model, we believe that it is not reasonable
to expect model developers to share their work to
this degree with all interested parties. Model de-
velopment uses a variety of skills and commonly
requires substantial investments of time, effort,
and creativity on the part of the modeler. Thus,
models are intellectual property which may be
used for multiple applications over time. As such,
modelers may choose to retain control over the
subsequent use of their models. In addition, mod-
els may incorporate proprietary information that
cannot be released. We recommend that when a
manuscript based on a model is submitted for
publication, electronic copies of the model be made
available to reviewers with the understanding that
they (and any proprietary information therein) re-
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main confidential. However, release of electronic
copies of models beyond this specific type of eval-
uation should be at the discretion of the modeler.
Data Sources
Models should be based on the highest quality
data available. However, most data sources used
for models will require some adjustment to correct
for biases [15'1. Whenever possible, data used as
the basis of models should be from epidemiologic
studies; randomized, controlled trials (RCTs); or
prospective naturalistic studies. In general, all rele-
vant trials, rather than a selected subset of trials,
should be used [20J. For some models, it may be
reasonable to use only certain selected trials (e.g.,
trials involving specific study populations, inclu-
sion/exclusion criteria, or comparators). If only se-
lected trials or other studies are used, justification
for the use of this subset must be provided.
Observational studies, retrospective data, and ex-
pert opinion (discussed separately below) are also
often used in models. These data sources have lim-
itations and can potentially result in biases; how-
ever, data from these sources can balance the in-
herent biases present in RCTs (see Data Quality,
below). Models are often used to develop estimates
of costs and outcomes with high external validity
(applicability to real world practices) based on in-
ternally valid RCT data.
Data from a number of different sources are of-
ten necessary for modeling. Appropriate methods
should be used in combining data from disparate
sources, such as random-effects meta-analysis [21].
While a discussion of meta-analysis techniques is
beyond the scope of these recommendations, it is
important that this technique be performed in a
rigorous and systematic fashion, generally includ-
ing incorporation of all relevant literature (or a jus-
tified subset). Study purposes and funding sources
should also be considered before including them in
an analysis. The Cochrane Collaboration [22], as
well as others, have developed guidelines for ap-
propriate performance of meta-analysis. Models
may combine and summarize data from various
sources similarly to meta-analyses; however, mod-
els commonly use and integrate broader types of
information than are acceptable for meta-analyses
[15].
Data Quality
While it is important to begin with the most rigor-
ous data available, both the quality and relevance
of these data must always be evaluated. Assess-
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ment of the quality of different types of data is dis-
cussed below.
Prospective Data. While prospective data used in
models can come from a number of types of stud-
ies, results from clinical trials are often used in
modeling. However, clinical trial data should not
be accepted as the gold standard for modeling
solely on the basis of coming from a prospective,
randomized, controlled setting. RCTs are not al-
ways well designed; and problems in trial design
can lead to spurious results. In addition, small tri-
als may be nonrepresentative and can lead to inac-
curate model parameters [6]. RCTs are commonly
designed to answer questions of safety and efficacy
in a specified (high internal validity) environment.
Generalizing their results to real-world treatment
patterns (going from efficacy to effectiveness) may
introduce biases. RCTs also commonly have set
(protocol-based) treatment patterns that involve
more extensive resource utilization than would
normally occur. In addition to increasing treat-
ment costs, this protocol-based resource utiliza-
tion may lead to the diagnosis of additional condi-
tions that would not have been detected outside of
the trial, potentially changing ultimate health out-
comes. Thus, the quality and relevance of data
from trials as well as other studies must be evalu-
ated prior to their use. The evaluation of prospec-
tive data quality should include: 1) availability
of data (e.g., have they been published in a peer-
reviewed journal?); 2) sample size; 3) period (dura-
tion) and frequency of data collection; 4) degree of
patient follow-up (i.e., all patients/intent to treat vs
only a subset of patients); 5) patient population
characteristics (e.g., inclusion/exclusion criteria);
and 6) methods of data collection (such as physician
case report form, patient self-administered survey,
structured interview, and information from a
proxy). When using information from RCTs, intent-
to-treat (ITT) data should always be used rather
than on-therapy results, as ITr findings correspond
more closely to real-world scenarios. Judgment on
whether the ITT scenario does reflect the real world
needs to be made. Similar criteria should be used to
evaluate other prospective (non-RCT) studies.
Retrospective Data. Many models include infor-
mation from retrospective studies, such as analysis
of healrhcare claims data. While retrospective data
clearly represent real-world practices (high external
validity), such data may be incomplete, incorrect,
or difficult to interpret. When collecting retrospec-
tive data, it may be useful to verify the accuracy of
a subset through patient interviews or medical chart
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abstraction; but in using retrospective data col-
lected or presented by other researchers, it is gen-
erally not feasible to perform any such direct as-
sessments of the accuracy. The completeness of a
retrospective dataset (whether the set contains all
data for all available, appropriate patients) must
also be assessed to ensure that the data were not
derived from a potentially biased subset or that
specific data elements are not systematically miss-
ing. Retrospective data are generally used to gather
information on resource utilization, diagnoses, and
patient demographic characteristics. The accuracy
and completeness of other retrospective data ele-
ments (e.g., disability status or days of work missed)
must be carefully assessed, as these types of data
are even more likely to be problematic. The spe-
cific patient population comprising the retrospec-
tive data must also be considered; they may not be
representative of patients in general, resulting in
nongeneralizable patterns of resource utilization
and costs. Furthermore, the types of data that can
be gathered from retrospective data are limited;
information on health outcomes, disease stage, and
non billable healthcare resource utilization (such as
telephone calls) are generally not present in retro-
spective data bases. Also, information on condi-
tions without specific ICD-9 or similar diagnosis
codes may not be available in retrospective
datasets, Of course, using sensitivity analyses with
retrospective data will help to overcome some of
the noted difficulties.
Costs. All economic models necessarily include
costs or charges. The quality of these values in terms
of source and perspective needs to be assessed.
These economic valuations are often obtained from
standard national sources; examples include the
Red Book or the Monthly Index of Medical Spe-
cialties (MIMS) for drug prices and Medicare max-
imum allowable charges, or the National Health
Service fee payment schedules for physician visits
and procedures. These values, however, may not
correspond to amounts actually charged; for ex-
ample, the average wholesale price (AWP) ob-
tained from the Red Book may be greater than the
acquisition cost paid by large managed care orga-
nizations but less than the out-of-pocket cost paid
by patients. However, these values do represent
agreed-upon standards and are a useful basis for
analysis. Economic values from other sources, such
as hospital charges, are generally less certain. The
source of any economic data and the methods
used to collect them must be evaluated. For exam-
ple, costs for laboratory tests can be derived from
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extensive time-and-motion studies, whereby the
costs of all components, including personnel, re-
agents, and overhead, are considered. ~rhile such
studies are very accurate, they arc costly, time-
consuming, and may produce results that vary tre-
mendously between healthcare institutions. Such
results would be of little use in models attempting
to project generalizable outcomes information. Al-
ternatively, these costs may be based on values
supplied by finance staff in one or more healthcare
settings. Such values can be collected in a less ex-
pensive and a more timely fashion but are associ-
ated with uncertain accuracy.
Many models also include indirect costs. These
costs include time lost from work or other produc-
tive activities due either to a clinical condition or
treatment for the condition by the patient or a care-
giver. Specification of indirect costs is currently an
area of some controversy, and a detailed discussion
of these costs is beyond the scope of these recom-
mendations. In general, a decision regarding the in-
clusion or exclusion of indirect costs in a model
will depend on the condition being modeled, the
perspective of the model, and the intended audi-
ence. As with direct costs, the source of and values
for indirect costs must be clearly specified if they
are included. For more information on specifica-
tion of indirect costs, see Koopmanschap and Rut-
ten [231 or Posnett and Jan [24].
Utilities. Models used for cost-utility analysis must
contain utility values that weigh relevant health
states. The source of utility weights should be as-
sessed. Utilities may be collected from the general
public (preferably the informed public), patients,
nurses, or physicians. The most appropriate source
of utilities is an area of debate. Gold er al. [2] rec-
ommend using utilities based on community val-
ues, that is, health state weights collected from
representative individuals from the general popula-
tion. The Canadian guidelines specify that while
the informed public is the appropriate source for
preference values for tax-supported issues, patients
may be used instead of the public, especially for
evaluating hypothetical health states f251. Smith et
al. [261 recommend collecting utilities from patients
being studied in the outcome model; healthcare
providers may be used as a surrogate. We recom-
mend using weights collected from non-healthcare
personnel, either patients or the informed public,
based on the model and study constraints. While
we acknowledge concerns from Gold et aI. that pa-
tients experiencing a disease may adapt to the con-
dition and thus rate health states more highly than
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would unaffected community members, it is also
possible that community members may not appre-
ciate or understand the full impact of a disease
health state in comparison to patients who are ac-
tually experiencing the state.
Utilities can be collected using linear scales (feel-
ing thermometer or visual analog scale), direct as-
sessment methods (standard gamble or time trade-
off), and multiattribute techniques using a variety
of instruments (e.g., Health Utility Index). The most
appropriate methodology for collecting utilities de-
pends in part on the condition or intervention un-
der study. In general, we recommend collecting
utilities from hypothetical health states using the
standard gamble. This methodology can be tailored
to the condition or intervention under study and is
likely to be the most sensitive. However, this ap-
proach requires a substantial amount of time and
money. In many cases, use of a multiattribute in-
strument will result in utilities of equivalent validity.
Such an instrument is generally easy to administer
and can produce results quickly and inexpensively.
The disadvantage of such an instrument is similar to
that of a generic quality of life instrument: it may
not be sensitive to changes in a given condition re-
sulting from a specific intervention.
Use of Expert Opinion
When data are not available from other sources,
opinions or judgments from qualified clinical ex-
perts are often used. Information from experts is
frequently needed to determine or confirm the ini-
tial structure of a model, including the relevant
treatment alternatives and outcomes. A variety of
model parameters, such as actual treatment pat-
terns for adverse events, must be obtained from
experts, as they arc generally not available from
"harder" sources such as clinical trials or retro-
spective data bases. Finally, expert judgment is an
important part of validating models, to ensure
that they conform to real-world practices and have
clinical face validity.
The selection of experts to participate in a model
may be a difficult process. It is important to in-
clude individuals with substantial credibility in
their fields, who are likely to be opinion leaders, as
well as from a range of practice settings and geo-
graphic locations. Experts can be identified by rec-
ommendations from other individuals in the study
area; by identification of the authors of recent rele-
vant publications; or by sponsor recommendation.
The credibility and reputation in the field of each
proposed expert should be evaluated before inclu-
sion. This is especially important when evaluating
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a new therapeutic intervention, where specialists
most familiar with the intervention are likely to
have the most current information yet may also
have biases towards the intervention. These ex-
perts should be balanced by others who are likely
to be more neutral or even skeptical towards the
intervention. The report from the Task Force on
Principles for Economic Analysis of Health Care
Technology [27] includes a more comprehensive
discussion of problems with bias.
The collection of expert opinion data can be
done individually or in groups using structured
workbooks, questionnaires, telephone conference
calls, or interviews. Data may be collected individ-
ually or in group meetings. The choice depends on
the type of information to be collected and the
subject area. Either method can be appropriate de-
pending on the circumstances. If individual data
collection is performed, we recommend having ex-
perts complete a structured workbook with predom-
inantly close-ended questions. Workbooks should
also include existing data for experts to supple-
ment, modify, or dispute. For group meetings, we
suggest between five and eight experts; fewer than
five participants is more likely to result in a single
expert dominating the meeting, while more than
eight can result in participants not having the
chance to fully express their opinions.
Hughes and Hughes [28] recommend pilot test-
ing of instruments used to collect expert opinion to
assess their validity and reliability before use.
However, use of expert opinion (and models in
general) is required when decisions are to be made
where data are lacking. For parameters assessed
using expert opinion, often no other source of in-
formation is available; thus, the validity of expert
opinion (i.e., how well it correlates with observed
clinical data) cannot be assessed. In addition, ex-
pert opinion is likely to change with time as more
data become available; assessment of reliability
(whether clinicians provide the same responses over
time) is therefore of limited usefulness. We do not
recommend extensive pilot testing of instruments
before collection of expert opinion. However, brief
expert review of these instruments to assure clar-
ity, completeness, and "face validity" is essential.
Clinical opinion is necessary and invaluable for
many models; however, it is often considered sus-
pect. Data obtained from expert opinion can cor-
rect for the biases and omissions present in clinical
trials or published studies. However, such data
can also contain errors or biases, including repre-
sentative bias (clinical events in a given class are
treated as equally likely, ignoring prior probabili-
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ties), availability bias (probability estimates arc in-
fluenced by frequent, recent, or vivid events), and
anchoring events (in estimating a series of proba-
bilities, the choice of the initial probability to be
estimated will affect the values for subsequent prob-
ability estimates) [29]. A number of techniques
should be used to improve subjective probability
estimates [30-32]. For example, the Delphi method
involves distributing opinion-derived information
to outside reviewers for comment and possible mod-
ification. We recommend using a modified Delphi
approach, where information from expert opinion
is reviewed by outside individuals and comments
from these outside reviewers are subsequently pre-
sented to the original experts. The experts then
have the opportunity to modify their opinions. The
Nominal Group Technique, a structured method
of eliciting ideas, ran kings, and choices between
alternatives, may also be appropriate for certain in-
formation generated by clinical opinion [31,33,34].
Simplicity/Complexity
As discussed by Drummond [201, models should
be optimal and based on reasonable time and ex-
pense-they do not need to be perfect. In develop-
ment and evaluation, it must be remembered that
models are generalizations that cannot represent
all the complexities of real clinical practice. Mod-
els should contain enough treatment complexity
to have face validity, but should not attempt to
capture every detail involved in individual patient
care. In general, models should be only as com-
plex as required. Branches representing events that
are theoretically possible but would never be cho-
sen in real life should not be developed or added
129]. Branches that more completely represent ac-
tual treatment patterns but do not significantly
impact projected outcomes should be removed or
combined with other branches. Conversely, all vari-
ables included in the model should represent im-
portant population or clinical factors [4]. Variables
that are not relevant to the condition, population,
or treatment strategies should be eliminated. Model
simplicity may be enhanced by designing the model
as a series of separate modules, each accomplish-
ing one specific goal, which can be evaluated indi-
vidually [19].
Model simplicity versus complexity is not a
straightforward issue. The degree of complexity
needed is based on numerous factors, including
the clinical condition, treatment alternatives, and
resource utilization, as well as on limitations in
available data, time, and budget. Necessary model
complexity is also likely to change over time, as
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additional information regarding healthcare con-
ditions or interventions is obtained. Choosing the
optimal balance between simplicity and complex-
ity is a skill that improves with experience. When
starting a new model, we recommend erring on
the side of too much complexity, then simplifying
the model as appropriate or feasible (it is generally
easier to remove components from an overly com-
plex model than to add new branches to an overly
simple model).
Treatment or Intervention Strategies and Outcomes
While striving to make models as simple as possi-
ble, all relevant treatment or intervention strategies
must be addressed. These may include strategies of
no action (e.g., watchful waiting) or palliation
only. A reasonable set of treatment alternatives,
which are neither overly complex nor missing im-
portant strategies, is based on review of published
literature and clinical trials as well as on expert
consultation. It may also be useful to include ex-
treme strategies (e.g., very aggressive or very pas-
sive treatment options) even if these are not proba-
ble treatment strategies. These extreme strategies
can serve as comparators for cost-effectiveness
analysis or as tests of model validity [41. A com-
mon error in models is to include actions or selec-
tion of treatment branches based on events that
cannot be or generally are not observed [8]. For
example, it would be incorrect to include a deci-
sion regarding alternative treatment based on bio-
chemical changes in an asymptomatic patient who
did not receive laboratory tests. The likelihood of
model events must be based on treatments, compli-
cations, test results, or other findings that would
normally be observed. However, changes in pa-
tient status (such as disease progression) may be
based on unobserved events (e.g., HIV viral load in
patients not receiving regular viral load assess-
ment) as long as these unobserved events do not di-
rectly trigger subsequent model activities depen-
dent upon knowledge of unobserved events.
As with treatment or intervention strategies,
models should include all relevant outcomes, in-
cluding negative consequences of healthcare inter-
ventions (e.g., the inclusion of adverse events and
their management across different settings and
countries). In addition to initial success and fail-
ure, outcomes may include relapse, adverse events,
discontinuation, loss to follow-up, or death. Inclu-
sion of only a subset of relevant outcomes could
result in incomplete evaluation of treatment strat-
egies, producing biased results. A complete set of
outcomes can be determined from review of clini-
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cal studies and consultation with experts, focusing
on what happens to all initially treated or partici-
pating patients.
In addition, models comparing alternative treat-
ments or interventions must provide outcomes that
are useful in making decisions between these alter-
native strategies. Intermediate outcomes (such as
short-term changes in serum cholesterol as an out-
come from a model evaluating alternative strategies
for hyperlipidemia) often do not provide sufficient
information for making informed decisions regard-
ing such choices; whereas final outcomes (reduc-
tion in hyperlipidemia-associated coronary heart
disease) may be more useful. Depending on the
needs of the involved decision makers, we recom-
mend that models generally include long-term or
final outcomes.
Model Structure
Specifics of the model need to be examined care-
fully. The steps, branches, or health states of the
model should follow the course of treatment or the
progression of the disease. If a model is evaluated
through the complete course of the disease or con-
dition under study, all modeled patients need to
end in "terminal states," that is, a final model out-
come such as cured, relapsed, or dead. However,
when models are used to evaluate treatments or in-
terventions for finite time intervals, which may not
include the end of the disease course, patients may
terminate the model in intermediate health states
such as receiving therapy or undiagnosed disease.
There should be logical restriction on the subse-
quent permissible series of steps in a model; only
certain model transitions will be allowable. For ex-
ample, in a postcardiac transplantation Markov
model [13], acute complications will either resolve
(resulting in the patient returning to the "well"
state) or prove fatal (leading to the "death" state);
patients cannot remain in an acute complication
state since by definition acute events are time-
limited. By contrast, once an individual enters a
chronic complication state, he remains in this state
until death and cannot return to the "well" state.
Clearly, individuals in a final state (death) cannot
return to an earlier condition.
All model probabilities must be between 0 and
1. When only mutually exclusive outcomes are
possible (e.g., survive vs die, improve vs stabilize vs
worsen), probabilities for the outcomes are re-
quired to sum to 1. When patients experience more
than one outcome (e.g., multiple types of adverse
events), probabilities may sum to more than 100%.
The model should also exhibit "symmetry"; that
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is, the modeled prognosis must be the same for the
same condition/treatment combinations in differ-
ent sections of the model [4]. In decision tree mod-
els, branch points can be broadly classified as ei-
ther decision nodes or chance nodes. Decision nodes
are used when alternative treatment strategies can
be chosen by patients or physicians. In contrast,
chance nodes are branch points where treatment
outcomes or other events occur based on random
likelihoods (represented by specified probabilities
or probability distributions). While other types of
models (such as simulations) may use different ter-
minology, the distinction between decision and
chance (i.e., volitional choices vs random events) is
important in all models.
Biases
There are numerous potential sources of bias in
models, some of which have been discussed above.
Several authors have advocated that model bias
must be applied consistently against the treatment
strategy producing the optimal outcome [4]. How-
ever, as the optimal outcome cannot be determined
until after the model is completed, it is difficult to
set the direction of bias as recommended during
development. It may be more feasible to record po-
tential biases and their directions in a log similar to
that recommended for assumptions (see Transpar-
ency). In any case, all suspected biases present in
models, including biases present by design, should
be discussed in any accompanying manuscript or
report, and the impact of the biases on model out-
comes should be explored. Making models as trans-
parent as possible (as discussed under Transpar-
ency) will help to ensure that biases are not hidden.
As discussed above, while models may contain bi-
ases, modeling is also a technique to remove biases
from other sources of data, such as RCTs.
Criteria Used after Model Development or
after Reviewing Model Design
Sensitivity Analysis
Sensitivity analysis involves varying key model pa-
rameter values to evaluate their impact on model
outcomes. Parameters with the greatest level of un-
certainty (e.g., values from expert opinion), the
greatest degree of variation, or the greatest influ-
ence on model outcomes must be included in sensi-
tivity analysis. The range of values to use in sensi-
tivity analysis can be based on statistical variation
for point estimates or on probability distributions
(e.g., Monte Carlo simulations) [41. Alternatively,
expert opinion may be used to evaluate the range
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of values a model parameter could reasonably as-
sume. While the model question must be clinically
relevant (as discussed in Clinical Relevance), pa-
rameters used in sensitivity analysis do not need to
be "reasonable"; however, justification for the
choice of values should be provided to maintain the
model's transparency. Inclusion of extreme strate-
gies-very passive or very aggressive treatment op-
tions and best/worst case scenarios-may be useful
to test the model's limits and provide outer bound-
aries for results. Threshold analysis (i.e., assessment
of the variable value at which comparative out-
comes are equal) is also often useful to delineate
the conditions under which alternative decisions
have equivalent consequences [35-37].
Some controversy exists regarding unidimen-
sional (altering one variable at a time) versus multi-
dimensional (altering multiple variables simulta-
neously) sensitivity analysis. While multidimensional
analysis may permit exploration of greater vari-
ability than does unidimensional, results of multi-
dimensional analysis are much harder to interpret.
In addition, multidimensional probability distri-
butions (for sensitivity analysis of stochastic mod-
els) are very difficult to derive. Multidimensional
sensitivity analysis can be performed using Monte
Carlo analysis; however, for spreadsheet models,
multidimensional sensitivity analysis may be diffi-
cult to perform for less experienced modelers. As
an alternative compromise strategy, we recommend
performing multidimensional sensitivity analysis
by simultaneously varying only correlated param-
eters. This strategy permits evaluation of a broader
range of variability (particularly useful in best case/
worst case scenarios) than does unidimensional
analysis, but provides easier interpretation of re-
sults than with independent modification of un-
correlated variables. It is also more important to
perform sensitivity analysis on variables that af-
fect early decisions, as the impact of these deci-
sions are propagated and amplified through the
subsequent branches. In all cases, an explanation
of selected sensitivity parameter values should be
provided.
Briggs and Sculpher [35J have discussed a num-
ber of uses for sensitivity analysis, including the
exploration of:
• The impact of extrapolation from intermediate
clinical endpoints or short-term findings to final/
long-term results;
• Generalization of results to a different popula-
tion;
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• Changes in discount rate;
• Inclusion of indirect costs.
Briggs and Sculpher also suggest performing sen-
sitivity analysis on costs, even those from "legiti-
mate" sources such as a national drug formulary.
However, costs from a national reference, whether
correct or not, are agreed-upon standards that per-
mit comparisons between different analyses. Thus,
we do not recommend performing sensitivity anal-
ysis on costs from these sources. If costs are uncer-
tain, they should have sensitivity analyses. Such
analyses are distinct from threshold analyses where
a cost is varied to determine the price where com-
parative outcomes have equal cost. Different sets of
costs can be used in a model when the results are to
be applied to different countries, types of insurers
or payment systems, or perspectives. However, this
is not a sensitivity analysis (changing model values
to observe their impact on model outcomes), but
rather an adaptation of the model to a new setting.
Sensitivity analysis involving changes of discount
rates merits specific consideration. The Panel of
Cost-Effectiveness in Health and Medicine recom-
mends using a base case discount rate of 3%, but
also using a rate of 5% in sensitivity analysis-ad-
ditional sensitivity analyses may vary the discount
rate between 0% and 7% [21. While we agree with
the Panel's recommendation for using 3% as the
base case discount rate in the United States (other
countries may have different recommendations),
we recommend only two additional discount rates
for sensitivity analysis: 0% (no discounting) and
7% (as a reasonable maximum rate). There is also
controversy as to whether the same discount rate
should be used for costs and health outcomes, or
whether these two measures should be differen-
tially discounted. The Panel of Cost-Effectiveness
in Health and Medicine recommends using the
same discount rate for both costs and outcomes
[2\. However, other researchers recommend using
a lower discount rate for outcomes than for costs
[38,39\. Ganiats [40] presents a compelling argu-
ment against requiring the same discount rates for
costs and outcomes. Hillman and Kim [411 also
discuss problems with discounting future health
outcomes, especially if used to set priorities among
alternative programs. The authors of this review
do not fully agree on the appropriate discounting
of outcomes relative to costs. We therefore recom-
mend the approach used by Canadian and other
healthcare authorities [251: a base case analysis
with equal discount rates for costs and outcomes
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plus supplemental analyses where costs are dis-
counted at a greater rate than outcomes.
Sensitivity analysis can identify key drivers-
model parameters such as event probabilities, med-
ical resource utilization rates, or costs-that are
most important in determining outcomes. Perhaps
the most important reason for performing sensitiv-
ity analysis is to determine whether it would be
worthwhile to seek better data for future decisions,
that is, whether key drivers (e.g., cost drivers) in
the model have a high degree of uncertainty and
need to be more accurately determined [161.
Verification
Model verification is the use of sensitivity analysis
to determine whether the model is performing ap-
propriately [4,191, which is a somewhat subjective
judgment. In general, model results should make in-
tuitive sense: cost and outcome projections should
seem realistic based on the disease condition and
previously documented treatment alternatives. For
example, as costs of medical resources are increased,
total projected costs should increase. Verification
often involves running the model under simplifying
assumptions, thereby limiting the type and range
of data values used for input [191- This type of sen-
sitivity analysis may also be helpful to convince
healthcare personnel and policy makers of the use-
fulness of a model [28).
In performing model verification, changes in cer-
tain model parameters may not produce the ex-
pected changes in results; this incongruity must be
evaluated. It could reflect model errors or unsus-
pected linkages between model values and outcomes.
The linkages can be important in understanding the
interaction between resource utilization and patient
outcomes.
Validation
Validation involves assessing whether model pro-
jections represent real-world outcomes. Simpson
[lS] distinguishes between structural validity (how
well the model represents the patterns seen in real-
world decisions) and content validity (how well the
data used reflects current knowledge and prac-
tices). In general, it is not possible to compare
model outcomes with actual events at the time of
model development (if actual data were available,
there would be no need for a model). Models can
be partially validated by comparing their results
with previously developed models (as discussed in
Model Scope). This validation is most convincing
if different types of models project similar out-
comes. However, when results from previously de-
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veloped models have not been published, such
model-to-model validation is rarely performed, in
part due to the proprietary nature of many models.
It may be possible to perform validation by
comparing select model results (such as intermedi-
ate outcomes) with available sources of data or
with previously developed models. For example, in
modeling a chronic condition, it may be possible to
validate short-term model projections with existing
clinical and economic data. Revicki et al. [421 used
this approach to validate the I-year model projec-
tions with existing information in an antidepres-
sant treatment model. For longer-term model esti-
mates, as clinical and economic data are obtained
over time, it is important to return to older models
and evaluate their validity; unfortunately, funding
for such post-hoc validations is rarely available.
Despite these difficulties, validation of models us-
ing data collected in subsequent studies is crucial
to increase the acceptance of modeling and further
develop this field.
Conclusions
There is currently considerable controversy regard-
ing the use of modeling in evaluating costs and
other outcomes resulting from healthcare interven-
tions. Some authors have stated that the appropri-
ate use of models is only for first resort (when little
or no data are available to evaluate very new tech-
nologies) or last resort (when no other techniques
are possible) [6]. Others have stated that models
should be used only "when it is impossible or im-
practical to gather data using adequate, well-con-
trolled studies" [20]. Perhaps the strongest com-
ment against modeling comes from Piccirillo and
Feinstein [37], who stated that "good clinical think-
ing does not (or should not) so easily reduce a pa-
tient to a flow chart of finite options that fail to in-
clude so many important clinical distinctions."
Much of this criticism ignores limitations of
other techniques for performing socioeconomic anal-
yses. While randomized clinical trials are consid-
ered the gold standard for evaluation of safety and
efficacy, they clearly have limitations in evaluating
costs and outcomes in a real-world context. Treat-
ment patterns, resource utilization, costs, and even
clinical outcomes in clinical trials, are often highly
influenced by the trial protocol, which may be set
up to satisfy regulatory requirements. Furthermore,
participants in clinical trials many not correspond
to the general population that will potentially re-
ceive the intervention under study. Other study mo-
dalities, such as observational studies or retrospec-
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rive analyses, also have limitations. The main
purpose of any model is as a policy tool, to help in-
form a decision maker, not to make the decision
[43]. In providing appropriate information, models
often need to go beyond the limits of data that are
available in standard clinical trials and similar
types of studies. This is a strength of modeling as a
methodology, not a weakness.
In addition, few authors have considered lim-
ited resources for evaluating the relative costs and
outcomes of new medical technologies, while they
consider overall limited resources for the use of
medical services. Although Knoebel [44] commented
that modeling is "costly, time-consuming and la-
bor- and expertise-intensive," model development
is much less costly, much more rapid, and more
flexible than prospective studies. Increasingly, so-
cioeconomic and quality of life information on all
new healthcare technologies is expected or required
by government agencies, insurers, and providers
worldwide. Given the limited resources available
for the development of new medical technologies
and the evaluation of public health interventions, it
is not feasible for pharmaceutical and medical de-
vice companies, government agencies, or profes-
sional societies to fund prospective effectiveness
studies (or similar methodologies) for all interven-
tions in all practice and clinical environments. Nei-
ther is it reasonable to expect decision makers to
wait for results from naturalistic trials. Modeling,
in collaboration with prospective studies, is a feasi-
ble and timely method for producing a wider range
of important socioeconomic data for responsible
decision making.
Finally, many authors ignore the likelihood that
in the absence of specifically developed models, cli-
nicians, public health officials, and other healthcare
decision makers will form their own internal (intui-
tive) models. For example, when evaluating patient
treatment strategies, clinicians develop mental mod-
els that project potential outcomes (both positive
and negative) and costs associated with the avail-
able treatment options. As discussed by Barr and
Schumacher [45], modeling can improve decisions
made using clinical judgment and can better define
the elements involved in the decision. External mod-
els provide a framework to assist with this internal
analysis, incorporating additional parameters and
socioeconomic outcomes that clinicians often do
not consider. When developed properly, such mod-
els permit the evaluation of new medical technolo-
gies without the potential (hidden) biases and self-
interest of the involved parties [44]. In addition,
through the process of modeling, decision-makers
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explicitly consider the outcomes resulting from al-
ternative choices and the uncertainty associated
with each choice and outcome [45]. In contrast to
the criticism by Piccirillo and Feinstein [37J pre-
sented above, models do not and should not be ex-
pected to represent the full complexity of actual pa-
tient care. Models involve multiple generalizations
and simplifications. However, the generalizations
and simplifications incorporated into models per-
mit evaluation of treatment alternatives for broad
groups of patients.
Not withstanding our belief that models are use-
ful, necessary, and should be employed in health-
care decision making to a greater degree, much
criticism of models has been justified. Many mod-
els involve incorrect structures, inappropriate pa-
rameters, and incomplete outcomes. Worse per-
haps, many models have been presented as black
boxes, where the data sources and model parame-
ters and branches cannot be evaluated. However,
as with all methodologies, there are good and less
than good models. Health outcomes modeling is a
relatively new discipline. As model users and devel-
opers become more sophisticated and experienced,
the standards they required for acceptable models
will also rise.
It is also important to note that models are com-
monly used and accepted in other fields, such as
manufacturing, banking, and telecommunications.
However, many individuals who could potentially
use models to better inform healrhcare decisions
have been resistant to their use. Some feel that
healthcare is inherently different from other fields
and cannot be represented using simplifications
and algorithms. Others feel that the use of models
intrudes on the role and autonomy of healthcare
providers. We disagree with these views and be-
lieve that modeling can playa major positive role
in healthcare. As discussed by Lilford 151, health-
care involves collecting, transferring, and analyz-
ing information. Computers are very good at col-
lecting and transferring information, and when the
analysis involves defined steps, computers can also
perform this activity. Thus, rather than interfering
with medical care, models can provide information
for healthcare decisions by carrying out simplified,
repetitive activities, which computers perform bet-
ter than humans.
While these recommendations have attempted
to provide a systematic framework for the devel-
opment and review of models, modeling, like the
practice of medicine itself, is in many aspects a
blending of both art and science. This is not meant
to justify or excuse inadequate models, but to clar-
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ify the difficulties involved in model development
and evaluation. As in other areas of clinical re-
search, there is almost always more than one cor-
rect way to evaluate a problem. A single, rigid for-
mulation for all model development is neither
desirable nor realistic. Development of models
thus reflects differences in creative thinking to ob-
tain the desired information as well as differences
in experience and preference for varied techniques.
These recommendations are not meant to be pre-
scriptive, indicating the accepted method for mod-
eling; rather, they are an attempt to systematize
the components and information needed as a basis
for model development and review. We hope that
the use of good practice recommendations for mod-
eling will not only improve the development and
review of models but also lead to greater accep-
tance of this methodology.
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